phase

ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)

ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)

SHANGHAI, May 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel…

14 hours ago
Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma TrialNicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial

Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial

Press Release Nicox Announces Results of the Exploratory Whistler Phase 3b Glaucoma Trial Several aqueous humor parameters stimulated by nitric oxide…

3 days ago
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

May 10, 2025 10:00 ET  | Source: Akero Therapeutics Inc. Analysis of EFX results with AI-based digital pathology underscores the…

6 days ago
ST Engineering iDirect Leads the European Protected Waveform Consortium into Phase 2ST Engineering iDirect Leads the European Protected Waveform Consortium into Phase 2

ST Engineering iDirect Leads the European Protected Waveform Consortium into Phase 2

Setting the EU standard for secure, adaptable and interoperable satellite communications to support military operations and the IRIS² constellation SINT-NIKLAAS,…

1 week ago
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp BurdenPreliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

In the Phase 2 open-label study, REC-4881 (4 mg QD) led to a median 43% reduction (n=6 patients) in polyp…

2 weeks ago
BlackfinBio Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial for Novel AAV Gene Therapy BFB-101 to Treat the Rare Neurological Disease Hereditary Spastic Paraplegia, Type 47 (SPG47)BlackfinBio Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial for Novel AAV Gene Therapy BFB-101 to Treat the Rare Neurological Disease Hereditary Spastic Paraplegia, Type 47 (SPG47)

BlackfinBio Announces FDA Clearance to Initiate Phase 1/2 Clinical Trial for Novel AAV Gene Therapy BFB-101 to Treat the Rare Neurological Disease Hereditary Spastic Paraplegia, Type 47 (SPG47)

April 28, 2025 04:00 ET  | Source: BlackfinBio CHESHIRE, United Kingdom, April 28, 2025 (GLOBE NEWSWIRE) -- BlackfinBio Ltd, a…

3 weeks ago
EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week 2025EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week 2025

EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease Week 2025

April 28, 2025 03:00 ET  | Source: EnteroBiotix EnteroBiotix Announces Oral Presentation of Phase 2a IBS-C Results at Digestive Disease…

3 weeks ago
Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBCProtara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

April 26, 2025 10:00 ET  | Source: Protara Therapeutics TARA-002 demonstrates 100% complete response rate at any time and 67%…

3 weeks ago
Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetesZealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes

Zealand Pharma announces first participant enrolled in Phase 2b ZUPREME-2 trial of petrelintide in people with overweight or obesity and type 2 diabetes

April 24, 2025 01:00 ET  | Source: Zealand Pharma Press release – No. 6 / 2025 Zealand Pharma announces first…

3 weeks ago
Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical ReadoutsCytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts

Cytovation Raises US$6m to Advance Phase 2 Development of CY-101 in Adrenocortical Carcinoma to First Clinical Readouts

April 23, 2025 03:00 ET  | Source: Cytovation New funds provided largely by existing investors, led by Sandwater  Phase 2…

3 weeks ago
Show more Posts